Antiviral Activity of Innate Immune Protein ISG15

Ronald N. Harty a Paula M. Pitha b Atsushi Okumura a

a Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pa., and 
b Biology Department, Johns Hopkins University, Baltimore, Md., USA

Introduction

The host innate immune response represents a critical, initial line of defense against invading pathogens, and the magnitude of this response can influence disease progression. The IFN system is a key component and complex regulator of innate immunity. Type I IFNs function primarily to promote an antiviral state in an infected host by inducing signaling through the IFN receptor to stimulate expression of a plethora of gene products that function in host defense. One of the early induced IFN-stimulated genes (ISGs), first identified more than 20 years ago, is a small ubiquitin-like protein termed ISG15 [1–3]. This review will summarize several recent reports that have contributed to our fundamental understanding of ISG15 antiviral activity, and which have provided novel insights into the mechanism(s) of the antiviral action exhibited by this broad-spectrum, IFN-induced, innate immune protein.

Ubiquitination versus ISGylation

Ubiquitin and ubiquitin-like proteins (e.g. ISG15 and SUMO) are small molecules expressed in eukaryotes that are conjugated to target proteins, often resulting in modulation of the target protein’s stability/function/localization [4]. The mechanisms by which proteins are ubiquitinated and ISGylated have many common features, and these
Protein modifiers regulate a diverse array of biological processes. These protein modification pathways have been reviewed in detail elsewhere [5, 6] (fig. 1), and thus will only be summarized here. Both ubiquitination and ISGylation result in covalent modification of target proteins following a series of enzymatic reactions that occur in a step-wise fashion (fig. 1). The process of ubiquitination begins with protease cleavage of precursor ubiquitin molecules at their C-termini to reveal the di-glycine motif. In the presence of ATP, the Gly-Gly motif is then adenylated by the ubiquitin activating enzyme (E1). The ubiquitin moiety is then transferred to a cysteine residue on a ubiquitin conjugating enzyme (E2). Finally, the ubiquitin moiety is then transferred to a cysteine residue on a ubiquitin conjugating enzyme (E2). The E2 enzyme in conjunction with a ubiquitin ligase (E3), which recognizes the specific target protein, transfers the ubiquitin moiety typically onto the ε-NH$_2$ group of a lysine residue of the substrate. In addition to lysine residues, other amino acids (e.g. serine/threonine) and the extreme N-termini of target proteins can potentially serve as target sites for ubiquitination and/or influence the ubiquitination process [7–9]. Proteins that are modified by poly-ubiquitination are often destined for degradation by the 26S proteasome. For example, this process is crucial in immune cells where protein ubiquitination regulates protein signaling pathways, innate and adaptive immune responses to pathogens, and expression of surface receptors [4, 5, 10, 11]. In contrast, mono-ubiquitination of proteins does not result in degradation, but rather can serve to modulate protein function, localization and/or sorting within the cell [4, 5, 11].

Unlike ubiquitination, ISGylation is an IFN-stimulated and regulated process that appears to mimic mono-ubiquitination functions, such as modulation of enzymatic activity, rather than the poly-ubiquitination function and protein degradation [12–16]. Like ubiquitination, ISGylation involves a cascade of enzymatic reactions involving E1, E2, and E3 enzymes. Briefly, ISG15 is synthesized as precursor protein (165 aa) that is like ubiquitin, subsequently cleaved to reveal di-glycine residues at its C-terminus in the form of a LRLRGG motif. This GG motif is adenylated in the presence of ATP, and ISG15 is then transferred sequentially from E1, E2 and E3 enzymes to its final destination on a lysine residue within the target substrate [11]. Because of the many similarities of the ubiquitination and ISGylation pathways, it is not surprising that there is some degree of overlap and competition between these pathways [17–21]. While the E1 enzymes are specific for ISGylation and ubiquitination, some of the enzymes that function in the ubiquitination pathway (e.g. E2 enzyme UbcH8) have a similar function in the ISGylation pathway [19, 21]. One of the features that is common to both pathways is that both ubiquitination and ISGylation are reversible. De-ubiquitinating enzymes and de-ISGylation enzymes (e.g. UBP43) function to cleave ubiquitin and/or ISG15 moieties from conjugated proteins [22–25]. De-ubiquitination and de-ISGylation provide an additional level of regulation in these pathways to maintain homeostasis [25].

**Ubiquitination and Virus Budding**

Over the last decade, numerous reports have demonstrated that the host ubiquitination machinery is linked to the process of budding or egress for many RNA virus fam-
In addition, the PPxY-type L-domain con-

ubiquitination process and/or viral L-domain function

Thus, small molecule inhibitors designed to block the

budding virions

includes: (1) the presence of free, excess ubiquitin within

virus budding in the presence of proteasome in-

ment of virus budding in the presence of proteasome in-

hibitors that deplete free ubiquitin in the cell [27-29, 34,

51x450]

51x654]

51x705]

51x692] implicated in regulating Gag-mediated budding of retro-

viruses, and subsequently linked to VP40-mediated bud-

ding of Ebola virus-like particles (VLPs) [27-30]. Several

lines of evidence linked ubiquitin with virus egress, in-

cluding: (1) the presence of free, excess ubiquitin within

budding virions [31], (2) detection of mono-ubiquitinated

forms of viral matrix proteins [30, 32-38] and (3) disrup-

tion of virus budding in the presence of proteasome in-

hibitors that deplete free ubiquitin in the cell [27-29, 34,

51x603]

51x462]

51x488] budding process of retroviruses, rhabdoviruses, filovirus-

has been linked or at least implicated to play a role in the

virus budding

51x527]. In sum, ubiquitination

51x118]

51x495] important insights into the molecular mechanisms by which

ISG15 functions as an innate antiviral protein with broad-

spectrum activity in vitro and in vivo. Results from sev-

eral of the most recent studies will be summarized below.

ISG15 Has Broad-Spectrum Antiviral Activity

While ubiquitin appears to be a broad-spectrum en-

hancer of virus production, ISG15 on the other hand ap-

pears to be a broad-spectrum inhibitor of virus produc-

tion. Antiviral activity associated with protein ISGylation

in vitro and/or in vivo has been reported for both DNA and

RNA viruses, including influenza A and B, Sindbis, hep-

atitis B, herpes simplex type-1, murine γ-herpesvirus, ve-

sicular stomatitis virus, lymphocytic choriomeningitis vi-

rus, respiratory syncytial virus, HIV-1 and Ebola virus

[59-64]. Recent studies have provided some new and im-

portant insights into the molecular mechanisms by which

ISG15 functions as an innate antiviral protein with broad-

spectrum activity in vitro and in vivo. Results from sev-

eral of the most recent studies will be summarized below.

ISG15 and Sindbis Virus

First, an elegant paper by Lenschow et al. [65] was of

significance as it helped to prove that protein ISGylation

and ISG15 possessed broad-spectrum antiviral activity in

an animal model of infection, and the findings under-

scored the importance of employing both in vitro and in

vivo models for analyses of antiviral mechanisms. One of

the major findings was that ISG15−/− mice were more

susceptible to Sindbis virus infection [66]. Although ISG15

conjugation was important for the observed antiviral effect,

the target substrate(s) for ISGylation was not identified. Since ISG15 is

now known to have more than 150 targets [11], the anti-

viral effect may be due to ISGylation of either a viral pro-

tein, a host protein, or both. Knowing the identity of the

target protein(s) will be instrumental in elucidating the

mechanism of action of ISG15 and for the possible devel-

opment of future antiviral strategies.

In a more recent report, the same group identified ar-

ginine-151 in mouse ISG15 as playing a key role in protein

ISGylation by mediating an interaction with UbE1L [66]. Indeed, an

R151A mutation attenuated the ability of ISG15 to inhibit replication of Sindbis virus in IFN-α/βR(−/−) mice, and mice lacking this the UbE1L enzyme

were highly susceptible to Sindbis virus infection [66]. In sum,

their results demonstrated that protein conjugation

is key for the antiviral effects of ISG15 in this animal

model of Sindbis virus infection [66].

ISG15 and HIV-1

IFN was shown to inhibit retroviral and lentiviral vi-

rion release [67, 68], and ISG15 was implicated in IFN-

mediated inhibition of HIV-1 [69, 70]. As ubiquitination

of Gag protein was shown to play a role in HIV-1 assem-

bly and budding, it seemed logical to hypothesize that

ISG15 could interfere with ubiquitination of Gag and

consequently disrupt this late stage of virus replication.

Indeed, recent findings indicated that this hypothesis

was correct. Okumura et al. [71] were the first to clearly

demonstrate that expression of ISG15 mimicked the an-

tiviral properties of IFN and blocked egress of HIV-1 from infected cells. The authors found that expression of

ISG15 appeared to block the ubiquitination process that

normally enhances HIV-1 Gag-mediated release of infec-
tious virus [71]. Interestingly, ISG15 did not affect syn-

thesis of viral proteins in the infected cell and, unlike the

Antiviral Activity of Innate Immune
Protein ISG15

J Innate Immun 2009;1:397–404
findings with other viral systems [65, 72], conjugation of ISG15 to either viral (HIV-1 Gag), or host (tsg101) proteins involved in budding was not evident [71]. However, ISG15 expression did disrupt the interaction between host tsg101 and the p6 domain of HIV-1 Gag. This virus-host interaction has been shown previously to be crucial for efficient budding of HIV-1. To further prove that the inhibitory effect on budding was specific for ISG15, the authors demonstrated that ISG15-specific siRNAs reversed the IFN-mediated inhibitory effect on HIV-1 release [71]. While the precise mechanism by which ISG15 interferes with the budding process of HIV-1 remains to be defined, the authors postulated that the decrease in ubiquitination of Gag and tsg101 may modify the binding affinity of this interaction or destabilize this complex. In addition, the authors noted that since components of the ubiquitination pathway were known to be targets for ISGylation [20, 73, 74], ISG15 may target one or more of the E1, E2, or E3 enzymes involved in HIV-1 egress. In sum, these findings were of significance in that: (1) they revealed an IFN-induced innate immune response that could target a late stage of HIV-1 replication, and (2) they suggested that ISG15 may have broad-spectrum antiviral activity against other RNA viruses that utilize L-domain/ubiquitination pathways for efficient egress.

**ISG15 and Ebola VLP Budding**

Most recently, independent studies from two groups revealed that ISG15 could inhibit budding mediated by the VP40 matrix protein of Ebola virus, and the mechanism of inhibition involved disruption of Nedd4-mediated ubiquitination of Ebola VP40 [75, 76] (fig. 1). Like HIV-1, the host ubiquitination pathway and E3 ubiquitin ligase Nedd4 have been linked to budding of negative-sense RNA virus such as Ebola virus and vesicular stomatitis virus (VSV) [30, 35, 39, 53, 55, 77]. In a prior publication, Malakhov et al. [23] identified Nedd4 as a binding partner for UbP43, an ISG15-deconjugating enzyme. Thus, Malakhova and Zhang [76] sought to determine whether Nedd4 could be targeted by ISG15 and whether this potential interaction would negatively regulate Nedd4 ligase activity. Indeed, the authors found that expression of ISG15 and the ISGylation system led to an overall decrease in Nedd4-ligase activity and Nedd4-mediated ubiquitination [76]. They demonstrated further that free ISG15 was sufficient to impair Nedd4 ligase activity both in vitro and in vivo [76]. Importantly, they determined that the molecular mechanism of ISG15-mediated inhibition of Nedd4 function was due to an abrogation of ubiquitin transfer from the E2 enzyme to the active site of Nedd4 [76], thus preventing Nedd4-mediated ubiquitination of target proteins.

As further proof of this novel mechanism, Malakhova and Zhang [76] utilized the Ebola VP40 VLP budding assay as a model system to assess Nedd4 function in the absence or presence of ISG15 and the ISGylation system. Indeed, they found that efficient budding of Ebola VP40 VLPs, which is dependent in part on Nedd4 function, was impaired in the presence of ISG15. The decrease in VP40 VLP release correlated well with an observed decrease in the detection of ubiquitinated forms of VP40. Lastly, budding of Ebola VP40 VLPs was shown to be enhanced in ISG15+/− knockout cells compared to that from normal murine embryonic fibroblasts [76], suggesting that endogenous levels of ISG15 can limit budding in unmanipulated cells.

In a simultaneous and independent report, our studies reached many of the same conclusions described above using both similar and distinct experimental approaches [75]. Prior to this study, we were one of the first groups to suggest that the ubiquitination process and Nedd4 ligase may be important for budding of Ebola VP40 VLPs, and that the PPxY-type L-domain within the VP40 protein was necessary for mediating interactions with the various WW-domains present within Nedd4 [30, 56]. Our main objective in this area of investigation was to elucidate the mechanism of Ebola VP40 VLP budding and host interactions at the molecular level in order to develop novel strategies or antiviral therapies to inhibit the budding process. In agreement with results of Malakhova and Zhang [76], we found that expression of ISG15 in the absence or presence of the ISGylation system (Ube1L and UbcH8) was able to inhibit budding of Ebola VP40 VLPs [75]. We have demonstrated not only that ISG15 interacted with Nedd4 ligase to inhibit ubiquitination of VP40, but also that ISG15-mediated inhibition of VP40 budding was dependent on the presence of VP40 L-domains. Indeed, budding of an L-domain deletion mutant of VP40 known to be insensitive to Nedd4-mediated ubiquitination, was also insensitive to ISG15-mediated inhibition of budding [75]. Lastly, inhibition of Ebola VP40 VLP budding by ISG15 was evident only in the presence of wild-type Nedd4, and not in the presence of a dominant-negative, enzymatically inactive mutant of Nedd4 [75]. Together, these findings revealed a previously undescribed mechanism of antiviral activity for ISG15.

Interestingly, like Malakhova and Zhang [76], our group was able to demonstrate that expression of ISG15...
also had an inhibitory effect on budding of VSV; a rhabdovirus that possesses a similar PPxY-type L-domain that interacts with Nedd4 ligase to promote efficient virion budding [75, 76]. Thus, ISG15-mediated inhibition of budding may not be limited to Ebola. We found that overexpression of ISG15 resulted in titers of wild-type VSV that were on average 10-fold lower than those measured in the absence of ISG15 [75]. Moreover, overexpression of ISG15 was found to have virtually no inhibitory effect on budding of VSV mutant PY>A4, a L-domain mutant of VSV that is insensitive to Nedd4-mediated ubiquitination [75]. Thus, viruses that utilize the host ubiquitination machinery for efficient egress may be susceptible to the inhibitory effect of ISG15.

**ISG15 and Influenza Virus**

As the above studies highlight, the antiviral activity of ISG15 against different viruses can be both dependent on or independent of ISG15 conjugation. In a recent study by Lai et al. [78], the authors demonstrate that antiviral activity of ISG15 against influenza B virus requires conjugation of ISG15 to target proteins. Although these authors had shown previously that mice lacking ISG15 were highly susceptible to influenza B virus infection, it was unclear whether ISG15 conjugation to target proteins was important for this antiviral activity. Using mice lacking the E1 activating enzyme for ISG15 conjugation (UbE1L−/− mice), the authors observed a 2–3 log increase in titers of influenza B virus in the lungs of these mice at 3 and 6 days after infection compared to those observed in wild-type mice [78]. In addition, the kinetics of lethality and survival observed in the UbE1L−/− mice infected with influenza B virus were essentially identical to those observed in ISG15−/− mice [78]. The authors concluded that the antiviral activity of ISG15 against influenza B virus in this in vivo model of infection is dependent on ISG15 conjugation; however, the identity of proteins targeted for ISGylation remains to be determined.

**Viruses Fight Back**

Viruses have evolved many elegant strategies to counteract host immune responses, particularly IFN-related pathways. Interestingly, several reports suggest that some viruses possess the ability to specifically counteract the antiviral effects of ISG15 and/or ISGylation. For example, one of the earliest reports by Yuan and Krug [72], demonstrated that the NS1 protein of influenza B virus prevents the activation of ISG15 by the E1 enzyme UbE1L, thus preventing ISG15 conjugation to target proteins. More recently, a unique strategy to inhibit both ubiquitination and ISGylation pathways was identified in nairoviruses and arteriviruses [79]. These viruses were shown to encode ovarian tumor domain-containing proteases capable of hydrolyzing both ubiquitin and ISG15 from target proteins [79]. Thus, the nairo- and arteriviruses appear to have developed a strategy to antagonize the antiviral effects of ISG15 [79]. Finally, in a comprehensive report by Guerra et al. [80], the authors not only demonstrate that ISG15 possesses antiviral activity against vaccinia virus, but also show that viral E3 protein can bind to ISG15 and disrupt its antiviral activity. Thus, a vaccinia virus strain lacking E3 (VVDeltaE3L) was unable to replicate in ISG15+/+ cells, but was able to replicate in ISG15-deficient cells [80]. Moreover, infection of ISG15−/− mice with VVDeltaE3L resulted in significant disease and mortality, which was not observed in ISG15+/+ mice infected with VVDeltaE3L [80]. The ability of other viruses to specifically target and abrogate ISGylation pathways as a means of immune evasion is of interest and awaits further investigation.

**Summary and Future Directions**

The host innate immune response is a critical first line of defense against invading viral pathogens. A better understanding of the distinct innate immune responses and the interplay between the virus and host is important for our understanding of immunopathogenesis, vaccine design, and development of new therapeutic strategies. The ISGs represent a vast array of proteins with a complex series of functions and outcomes. However, rapid progress has been made into this dynamic area of innate immunity, and the reports summarized here highlight some recent and insightful findings on the antiviral activity of ISG15. Despite these advancements, many gaps in our knowledge of the molecular mechanisms of ISG15 antiviral activity remain to be addressed. Some areas for further investigation include: (1) identifying the viral and/or host target proteins for ISG15 in viral infections where ISG15 conjugation is required for its antiviral activity; (2) determining whether expression and/or conjugation of ISG15 impairs replication, budding, and pathogenesis of infectious Ebola virus in cell culture and in the ISG15 animal models of infection; (3) determining whether ISG15 inhibits assembly/budding of additional L-do-
main-containing RNA viruses (e.g. Marburg virus) that likely utilize ubiquitination pathways for efficient replication and spread; (4) development of novel strategies to modulate the ISGylation system in an effort to enhance the innate immune response and more effectively combat viral infections, and (5) investigating the functional overlap of cellular ubiquitination and ISGylation pathways, the potential regulatory cross talk between these pathways, and their role in immune responses to invading pathogens.

Acknowledgments

This work was supported in part by NIH grant AI-077014-02 to R.N.H and by AI-19737-23 to P.M.P. The authors thank Leslie King for critically reviewing the manuscript.

References

1 Korant BD, Blomstrom DC, Jonah GJ, Knight E Jr: Interferon-induced proteins. Purification and characterization of a 15,000 dalton protein from human and bovine cells induced by interferon. J Biol Chem 1984;259:14835–14839.

2 Blomstrom DC, Fahey D, Kutny R, Korant BD, Knight E Jr: Molecular characterization of the interferon-induced 15-kDa protein: molecular cloning and nucleotide and amino acid sequence. J Biol Chem 1986;261:8811–8816.

3 Haas AL, Ahrens P, Bright PM, Ankel H: Interferon induces a 15-kilodalton protein exhibiting marked homology to ubiquitin. J Biol Chem 1987;262:11315–11323.

4 Herrmann J, Lerman LO, Lerman A: Ubiquitin and ubiquitin-like proteins in protein regulation. Circ Res 2007;100:1276–1291.

5 Petroski MD: The ubiquitin system, disease, and drug discovery. BMC Biochem 2008;9(suppl 1):S7.

6 Staub O: Ubiquitylation and isgylation: overlapping enzymatic cascades do the job. Sci STKE 2004;2004:pe43.

7 Amir RE, Haeccker H, Karin M, Ciechanover A: Mechanism of processing of the NF-kappa B2 p100 precursor: identification of the specific polyubiquitin chain-anchoring lysine residue and analysis of the role of NEDD8-ubiquitination on the SCF(beta-TrCP) ubiquitin ligase. Oncogene 2004;23:2540–2547.

8 Dada LA, Welch LC, Zhou G, Ben-Saadon R, Ciechanover A, Sznajder JI: Phosphorylation and ubiquitination are necessary for NF-ATPase endocytosis during hypoxia. Cell Signal 2007;19:1893–1898.

9 Sadeh R, Breitschopf K, Bercovich B, Zoabi M, Kavtsova-Ivanitsv K, Kornitzer D, Schwartz A, Ciechanover A: The N-terminal domain of MyD8 is necessary and sufficient for its nuclear localization-dependent degradation by the ubiquitin system. Proc Natl Acad Sci USA 2008;105:15690–15695.

10 Bibeau-Poirier A, Servant MJ: Roles of ubiquitination in pattern-recognition receptors and type I interferon receptor signaling. Cytokine 2008;43:359–367.

11 Kerscher O, Felberbaum R, Hochstrasser M: Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu Rev Cell Dev Biol 2006;22:159–180.

12 Dao CT, Zhang DE: ISG15: a ubiquitin-like enigma. Front Biosci 2005;10:2701–2722.

13 Kim KI, Zhang DE: ISG15, not just another ubiquitin-like protein. Biochem Biophys Res Commun 2003;307:431–434.

14 Ritchie KJ, Zhang DE: ISG15: the immunological kin of ubiquitin. Semin Cell Dev Biol 2004;15:237–246.

15 Martensen PM, Justesen J: Small ISGs coming forward. J Interferon Cytokine Res 2004;24:1–19.

16 Andersen JB, Hassel BA: The interferon regulated ubiquitin-like protein, ISG15, in tumorigenesis: friend or foe? Cytokine Growth Factor Rev 2006;17:411–421.

17 Zou W, Zhang DE: The interferon-inducible ubiquitin-protein isopeptide ligase (E3) EFP also functions as an ISG15 E3 ligase. J Biol Chem 2006;281:3989–3994.

18 Zou W, Papov V, Malakhova O, Kim KI, Dao C, Li J, Zhang DE: ISG15 modification of ubiquitin E2 Ubc13 disrupts its ability to form a hetero-ubiquitin bond with ubiquitin. Biochem Biophys Res Commun 2005;336:61–68.

19 Zhao C, Beaudenon SL, Kelley ML, Waddell MB, Yuan W, Schulman BA, Huibregtse JM, Krug RM: The UbcH8 ubiquitin E2 enzyme is also the E2 enzyme for ISG15, an IFN-alpha/beta-ubiquitin-like protein. Proc Natl Acad Sci USA 2004;101:7578–7582.

20 Takeuchi T, Iwahara S, Sakiyama S, Assajina H: Ubiquitin mediates optimal interferon (IFN) signaling by ISG15 conjugation. J Biol Chem 2005;280:25155–25162.

21 Kim KI, Giannakopoulos NV, Virgin HW, Zhang DE: Interferon-inducible ubiquitin E2, Ubc8, is a conjugating enzyme for protein ISGylation. Mol Cell 2004;24:9592–9600.

22 Catic A, Fiebiger E, Korbel GA, Blom D, Galardy PJ, Ploegh HL: Screen for ISG15-crossreactive deubiquitinas. PLoS ONE 2007;2:e679.

23 Malakhov MP, Malakhova OA, Kim KI, Ritchie KJ, Zhang DE: UBP43 (USP18) specifically removes ISG15 from conjugated proteins. J Biol Chem 2002;277:9976–9981.

24 Nicholson B, Leach CA, Goldenberg SJ, Francis DM, Kodrasov MP, Tian X, Shanks J, Sterner DE, Bernal A, Mathen MR, Wilkinson KD, Butt TR: Characterization of ubiquitin and ubiquitin-like-protein isopeptide-dase activities. Protein Sci 2008;17:1035–1043.

25 Singhal S, Taylor MC, Baker RT: Deubiquitylating enzymes and disease. BMC Biochem 2008;9(suppl 1):S3.

26 Chen BJ, Lamb RA: Mechanisms for enveloped virus budding: can some viruses do without an ESCRT? Virology 2008;372:221–232.

27 Strack B, Calistrri A, Accola MA, Palu G, Gottlinger HG: A role for ubiquitin ligase recruitment in retrovirus release. Proc Natl Acad Sci USA 2000;97:13063–13068.

28 Schubert U, Ott DE, Chertova EN, Welker R, Tessmer U, Princicotta MF, Bennink JR, Krausslich HG, Yewdell JW: Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2. Proc Natl Acad Sci USA 2000;97:13057–13062.

29 Patnaik A, Chau V, Wills JW: Ubiquitin is part of the retrovirus budding machinery. Proc Natl Acad Sci USA 2000;97:13069–13074.

30 Harty RN, Brown ME, Wang G, Huibregtse J, Hayes FP: A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: implications for filovirus budding. Proc Natl Acad Sci USA 2000;97:13871–13876.
Antiviral Activity of Innate Immune Protein ISG15

Patterman D, Pepinsky RB, Vogt VM: Ubiquitin in avian leukemia virus particles. Virology 1990;176:633–637.

Heidecker G, Lloyd PA, Fox K, Nagashima K, Derse D: Late assembly motifs of human T-cell leukemia virus type 1 and their relative roles in particle release. J Virol 2004;78:6636–6648.

OTT DE, Coren LV, Copeland TD, Kane BP, Johnson DG, Sowder RC 2nd, Yoshinaka Y, Oroszlan S, Arthur LO, Henderson LE: Ubiquitin is covalently attached to the p6Gag proteins of human immunodeficiency virus type 1 and simian immunodeficiency virus and to the p2Gag protein of Moloney murine leukemia virus. J Virol 1998;72:2962–2968.

OTT DE, Coren LV, Sowder RC 2nd, Adams J, Nagashima K, Schubert U: Equine infectious anemia virus and the ubiquitin-proteasome system. J Virol 2002;76:3038–3044.

Harty RN, Brown ME, McGettigan JP, Wang G, Jayakar HR, Huibergtse JM, Whitt MA, Schnell MJ: Rhabdoviruses and the cellular ubiquitin-proteasome system: a budding interaction. J Virol 2001;75:10623–10629.

Vana ML, Tang Y, Chen A, Medina G, Carter C, Leis J: Role of Nedd4 and ubiquitination of Roux sarcoma virus Gag in budding of virus-like particles from cells. J Virol 2004;78:13943–13953.

Jager S, Gottwein E, Krausslich HG: Ubiquitination of human immunodeficiency virus type 1 Gag is highly dependent on Gag membrane association. J Virol 2007;81:9193–9201.

Gottwein E, Jager S, Habermann A, Krausslich HG: Cumulative mutations of ubiquitin acceptor sites in human immunodeficiency virus type 1 gag cause a late budding defect. J Virol 2006;80:6267–6275.

Taylor GM, Hanson PI, Klilian M: Ubiquitin depletion and dominant-negative VPS4 inhibit rhabdovirus budding without affecting alphavirus budding. J Virol 2007;81:13631–13639.

OTT DE, Coren LV, Sowder RC 2nd, Adams J, Schubert U: Retroviruses have differing requirements for proteasome function in the budding process. J Virol 2003;77:3384–3393.

Calistri A, Del Vecchio C, Salata C, Celestino M, Celegato M, Gottlinger H, Palu G, Parolin C: Role of the feline immunodeficiency virus L-domain in the presence or absence of Gag processing: involvement of ubiquitin and Nedd4–2s ligase in viral egress. J Cell Physiol 2009;218:175–182.

Medina G, Pincetic A, Ehrlich LS, Zhang Y, Tang Y, Leis J, Carter CA: Tsg101 can replace Nedd4 function in ASV Gag release but not membrane targeting. Virology 2008;377:30–38.

Usami Y, Popov S, Popova E, Gottlinger HG: Efficient and specific rescue of human immunodeficiency virus type 1 budding defects by a Nedd4-like ubiquitin ligase. J Virol 2008;82:4898–4907.

Chung HY, Morita E, von Schwedler U, Muller B, Krausslich HG, Sundquist WI: Nedd4L overexpression rescues the release and infectivity of human immunodeficiency virus type 1 constructs lacking PTAP and YPXL late domains. J Virol 2008;82:4884–4897.

Zhdina M, McClure MO, Johnson MC, Biennais PD: Ubiquitin-dependent virus particle budding without viral protein ubiquitination. Proc Natl Acad Sci USA 2007;104:20031–20036.

Heidecker G, Lloyd PA, Soheilian F, Nagashima K, Derse D: The role of WWP1–Gag interaction and Gag ubiquitination in assembly and release of human T-cell leukemia virus type 1. J Virol 2007;81:9769–9777.

Uraga S, Noda T, Kawaoka Y, Yokosawa H, Yasuda J: Cellular factors required for Lassa virus budding. J Virol 2006;80:4191–4195.

Segura-Morales C, Pescia C, Chatellard-Causse C, Sadoul R, Bertrand E, Basyuk E: Tsg101 and Alix interact with murine leukemia virus Gag and cooperate with Nedd4 ubiquitin ligases during budding. J Biol Chem 2005;280:27004–27012.

Klinger PP, Schubert U: The ubiquitin-proteasome system in HIV replication: potential targets for antiretroviral therapy. Expert Rev Anti Infect Ther 2005;3:61–79.

Martin-Serrano J, Eastman SW, Chung W, Liotta JL, Tangy F, Abriel H, Staub O, Dokhelar MC, Abadie JB, Orlova O, Bunch TS: Overlapping Tsg101 and Nedd4 interact with the L domain of Rous sarcoma virus. J Virol 2004;78:9987–9992.

Fernandez-Fernandez M, Celegato M, Gottlinger H, Palu G, Parolin C: Tsg101-mediated ubiquitination and subsequent recruitment of Tsg101 ensure HTLV-1 Gag trafficking towards the multivesicular body pathway prior to virus budding. J Cell Sci 2004;117:2357–2367.

Sakurai A, Yasuda J, Takano H, Tanaka Y, Hatakeyama M, Shida H: Regulation of human T-cell leukemia virus type 1 (HTLV-I) budding by ubiquitin ligase Nedd4. Microbes Infect 2004;6:150–156.

Yasuda J, Nakao M, Kawaoka Y, Shida H: Nedd4 regulates egress of Ebola virus-like particles from host cells. J Virol 2003;77:9987–9992.

Gottwein E, Boden J, Muller B, Schmechel A, Zentgraf H, Krausslich HG: The Mason-Pfizer monkey virus PYY and PSAP motifs both contribute to virus release. J Virol 2003;77:9474–9485.

Timmins J, Schoenh G, Ricard-Blum S, Cinamaniaco S, Vernet T, Ruigrok RW, Weisenhorn W: Ebola virus matrix protein VP40 interaction with human cellular factors Tsg101 and Nedd4. J Mol Biol 2003;326:493–502.

Licata JM, Simpson-Holley M, Wright NT, Han Z, Paragas J, Hart RN: Overlapping motifs (PTAP and PPEY) within the Ebola virus VP40 protein function independently as late budding domains: involvement of host proteins TSG101 and VPS-4. J Virol 2003;77:1812–1819.

Yasuda J, Hunter E, Nakao M, Shida H: Functional involvement of a novel Nedd4-like ubiquitin ligase on retrovirus budding. EMBO Rep 2002;3:636–640.

Kikkoyogo A, Bouamr F, Vana ML, Xiang Y, Aiyar A, Carter C, Leis J: Proteins related to the Nedd4 family of ubiquitin protein ligases interact with the L domain of Roux sarcoma virus and are required for gag budding from cells. Proc Natl Acad Sci USA 2001;98:11199–11204.

Sadler AJ, Williams BR: Interferon-inducible antiviral effectors. Nat Rev Immunol 2008;8:559–368.

Pitha-Rowe IF, Pitha PM: Viral defense, carcinogenesis and ISG15: novel roles for an old ISG. Cytokine Growth Factor Rev 2007;18:409–417.

Sen GC, Sarkar SN: The interferon-stimulated genes: targets of direct signaling by interferons, double-stranded RNA, and viruses. Curr Top Microbiol Immunol 2007;316:233–250.

Kim JH, Liao JK, Zhang DE: The level of hepatitis B virus replication is not affected by protein ISG15 modification but is reduced by inhibition of UBPR4 (USP18) expression. J Immunol 2008;181:6467–6472.

Osaki A, Utermohlen O, Niendorf S, Horak I, Knobeloch KP: ISG15, an interferon-stimulated ubiquitin-like protein, is not essential for STAT1 signaling and responses against vesicular stomatitis and lymphocytic choriomeningitis virus. Mol Cell Biol 2005;25:6338–6345.

Moore EC, Barber J, Tripp RA: Respiratory syncytial virus (RSV) attachment and non-structural proteins modify the type I interferon response associated with suppressor of cytokine signaling (SOCS) proteins and IFN-stimulated gene-15 (ISG15). Virol J 2008;5:116.

Lenschow DJ, Lai C, Fria-Staheli N, Gianakopoulos NV, Lutz A, Wolff T, Osaki A, Levine B, Schmidt RE, Garcia-Sastre A, Leib DA, Pekosz A, Knobeloc KP, Horak I, Vivigin HW 4th: IFN-stimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses. Proc Natl Acad Sci USA 2007;104:1371–1376.

Giannakopoulos NV, Arutyunova E, Lai C, Johnson DG, Sowder RC 2nd, Yoshinaka Y, Oroszlan S, Arthur LO, Henderson LE: Ubiquitin is covalently attached to the p6Gag proteins of human immunodeficiency virus type 1 and simian immunodeficiency virus and to the p2Gag protein of Moloney murine leukemia virus. J Virol 1998;72:2962–2968.
67 Pitha PM, Staal SP, Bolognesi DP, Denny TP, Rowe WP: Effect of interferon on murine leukemia virus infection. II. Synthesis of viral components in exogenous infection. Virology 1977;79:1–13.
68 Pitha PM, Rowe WP, Oxman MN: Effect of interferon on endogenous, exogenous, and chroniv murine leukemia virus infection. Virology 1976;70:324–338.
69 Kunzi MS, Pitha PM: Interferon targeted genes in host defense. Autoimmunity 2003;36:457–461.
70 Kunzi MS, Pitha PM: Role of interferon-stimulated gene ISG-15 in the interferon-omega-mediated inhibition of human immunodeficiency virus replication. J Interferon Cytokine Res 1996;16:919–927.
71 Okumura A, Lu G, Pitha-Rowe I, Pitha PM: Innate antiviral response targets HIV-1 release by the induction of ubiquitin-like protein ISG15. Proc Natl Acad Sci USA 2006;103:1440–1445.
72 Yuan W, Krug RM: Influenza B virus NS1 protein inhibits conjugation of the interferon (IFN)-induced ubiquitin-like ISG15 protein. Embo J 2001;20:362–371.
73 Takeuchi T, Yokosawa H: ISG15 modification of Ubc13 suppresses its ubiquitin-conjugating activity. Biochem Biophys Res Commun 2005;336:9–13.
74 Takeuchi T, Yokosawa H: Detection and analysis of protein ISGylation. Methods Mol Biol 2008;446:139–149.
75 Okumura A, Pitha PM, Harty RN: ISG15 inhibits Ebola VP40 VLP budding in an L-domain-dependent manner by blocking Nedd4 ligase activity. Proc Natl Acad Sci USA 2008;105:3974–3979.
76 Malakhova OA, Zhang DE: ISG15 inhibits Nedd4 ubiquitin E3 activity and enhances the innate antiviral response. J Biol Chem 2008;283:8783–8787.
77 Martin-Serrano J, Perez-Caballero D, Bieniasz PD: Context-dependent effects of L domains and ubiquitination on viral budding. J Virol 2004;78:5554–5563.
78 Lai C, Struckhoff JJ, Schneider J, Martinez-Sobrido L, Wolff T, Garcia-Sastre A, Zhang DE, Lenschow DJ: Mice lacking the ISG15 E1 enzyme Ube1l demonstrate increased susceptibility to both mouse-adapted and nonmouse-adapted influenza B virus infection. J Virol 2009;83:1147–1151.
79 Frias-Staheli N, Giannakopoulos NV, Kikkert M, Taylor SL, Bridgen A, Paragas J, Richt JA, Rowland RR, Schmaljohn CS, Lenschow DJ, Snijder EJ, Garcia-Sastre A, Virgin HW: Ovarian tumor domain-containing viral proteases evade ubiquitin- and ISG15-dependent innate immune responses. Cell Host Microbe 2007;2:404–416.
80 Guerra S, Caceres A, Knobeloch KP, Horak I, Esteban M: Vaccinia virus E3 protein prevents the antiviral action of ISG15. PLoS Pathog 2008;4:e1000096.